Galecto, Inc. stock is up 17.17% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 December’s closed higher than November.
Galecto, Inc. develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the. treatment of myelofibrosis. GB0139, an inhaled. inhibitor of galectin-3 that is in. Phase IIb clinical trials for severe fibrotic lung diseases.